Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Basilea Pharmaceutica (SIX: BSLN)

Last close As at 04/11/2024

CHF43.20

▲ 0.40 (0.93%)

Market capitalisation

CHF564m

Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.

There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Cresemba, Zevtera and fosmanogepix could be significant.

Latest Insights

View More

Healthcare | Flash note

Basilea Pharmaceutica — Milestone march continues for Cresemba

Healthcare | Update

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Healthcare | Flash note

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Healthcare | Flash note

Basilea Pharmaceutica — EU paediatric approval triggers CHF10m milestone
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

Balance Sheet

Forecast net debt (CHFm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (7.7) 7.7 21.2
Relative (4.7) 12.5 6.8
52 week high/low CHF47.1/CHF32.2

Financials

Basilea Pharmaceutica has reported another US$1.25m milestone payment from its partner Pfizer in Asia-Pacific and China, triggered by Cresemba sales in this region crossing a pre-defined threshold. This is the fourth milestone payment for Cresemba from the region this year, adding to the already strong H2 results (c CHF33m/US$38.5m milestone payments recorded in H224 so far; CHF35m in 2024 to date). The Asia-Pacific region, particularly China (which accounts for c 20% of the market potential for Cresemba), is of key importance to Basilea, as its lead product approaches maturity in the US and European markets (exclusivity until late 2027). Note that Cresemba has recorded in-market sales of US$505m for the 12 months ending 30 June 2024, robust 20% y-o-y growth.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (CHFc) P/E (x) P/CF (x)
2022A 147.8 19.6 12.3 104.10 41.1 N/A
2023A 157.6 20.8 10.8 89.66 47.7 N/A
2024E 203.0 44.1 38.9 499.44 8.6 N/A
2025E 219.1 55.5 50.7 419.42 10.2 N/A

Research

Update

Healthcare

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Flash note

Healthcare

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

Healthcare

Flash note

Basilea Pharmaceutica — Milestone march continues for Cresemba
View All

Further insights

insight

Healthcare

Antibiotic resistance

insight

Healthcare

Antibiotics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free